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We explored the binding of octamer (Oct) transcription factors to the HIV-1 long terminal repeat (LTR) by gel shift assays and showed
none of the previously identified four potential Oct binding sites bound Oct-1 or Oct-2. Overexpression of Oct-1 or Oct-2 had no effect on
HIV-1 LTR activity in transiently transfected primary human CD4 T cells. Next, primary human CD4 T cells were co-transfected with a green
fluorescent protein (GFP)-expression vector and an Oct-1 or Oct-2 expression plasmid. The transfected cells were stimulated for 2 days and
then infected with the NL4-3 strain of HIV-1. After 3 days of infection, there were no differences in HIV-1 p24 supernatant levels. Apoptosis
of infected or bystander cells overexpressing Oct-1 or Oct-2 compared to control was also unaffected. Our studies demonstrate that Oct-1 and
Oct-2 fail to bind to the HIV-1 LTR and have no effect on HIV-1 transcription in primary human CD4 T cells.
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HIV-1, the cause of AIDS, still remains a leading cause of
morbidity and mortality worldwide. Because of its facile
ability to mutate in response to anti-retroviral therapy, the
virus remains a formidable foe. Some regions of the HIV-1
genome, however, are less likely to mutate without signifi-
cantly disrupting the viral life cycle. The HIV-1 transcrip-
tional promoter/long terminal repeat (LTR) is one such
region, particularly the proximal transcription factor binding
sites. As a true parasite, the integrated HIV-1 provirus is
dependent on the binding of host cellular transcription factors
to a variety of DNA sequences located within the LTR of the
viral genome for efficient replication (Al-Harthi and Roe-
buck, 1998; Cullen and Greene, 1989; Greene, 1990).
Much progress has been made during the past decade and
a half in terms of defining cellular transcription factors, such
as stimulating protein 1 (SP1), nuclear factor nB (NF-nB),
and nuclear factor of activated T-cells (NFAT), that bind0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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transcription start site (TSS). These cellular factors play
essential roles in stimulating the activity of the HIV-LTR in
response to a variety of cellular stimuli (Cron et al., 2000;
Harrich et al., 1989; Nabel and Baltimore, 1987). Never-
theless, there is still much to be learned about host cell
transcription factors that regulate HIV-1 transcription, in-
cluding those that bind within an upstream region of the
LTR called the negative regulatory element (NRE). The
NRE was so named because it has been shown to reduce the
activity of the HIV-1 LTR (Siekevitz et al., 1987).
Based on weak homology to the consensus octamer
transcription factor (Oct) binding motif, 5V ATGCAAAT
3V (Falkner and Zachau, 1984; Parslow et al., 1984), Liu
and Latchman (1997) identified four potential Oct binding
sites within the HIV-1 LTR. Three of these sites are located
within or nearby the NRE, and the fourth is situated
immediately upstream of the TSS (Fig. 1). They further
reported that overexpression of either Oct-1 or Oct-2 in a
fibroblast cell line markedly inhibited HIV-1 LTR transcrip-
tional activity and its transactivation by Tat protein (Liu and
Latchman, 1997). Although Oct-1 is constitutively ex-
pressed in most cell types, Oct-2 expression is largely
restricted to lymphocytes. In T cells, Oct-1 and Oct-2 have
Fig. 1. Potential octamer binding sites within the HIV-1 LTR. The four potential octamer binding sites (OCT) are noted. Numbering below the bar is relative to
the transcription start site nucleotide (+1). Abbreviations: NFAT, nuclear factor of activated T cells; NFnB, nuclear factor kappa B; NRE, negative regulatory
element; SP1, stimulating protein 1; TAR, transactivating region; TSS, transcription start site. For the four putative OCT sites in the HIV-1 LTR, the following
oligonucleotides (including the Oct consensus oligonucleotide) were used during EMSA in these studies: site 1 (369 to 376 bp of non-coding strand)
5VGTGTAGTTCTGCTAATCAGGGA3V; site 2 (232 to 226 bp of coding strand) 5VAGCCTGCATGGGATGGATGACC3V; site 3 (168 to 174 bp of non-
coding strand) 5VGGCCACGTGATGAAATGCTAGG3V; site 4 (7 to 14 bp of non-coding strand) 5VCCAGTACAGGCAAAAAGCAGCT3V; and Oct
consensus (human immunoglobulin kappa promoter; Staudt et al., 1986) 5VTGAGGGTATGCAAATTATTAAG3V. The core Oct sequence residues are italicized
and the identical residues in the HIV-1 LTR sites are underlined.
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activity by binding to two cis-elements within the proximal
IL-2 promoter (Cron et al., 2001; Kamps et al., 1990). In
addition to acting as positive regulators of transcription,
however, Oct proteins have also been shown to inhibit
transcription of a variety of genes (Wysocka and Herr,
2003). One example of this is the ability of Oct-1 and Oct-2
to inhibit IL-4 promoter activity in primary human CD4 T
cells by blocking the binding of NFAT transcriptional
activators to two surrounding NFAT binding sequences in
the proximal IL-4 promoter (Cron et al., 2001). Thus, Oct
proteins could theoretically be manipulated to inhibit HIV-1
transcription in lymphocytes.
Unlike fibroblasts, CD4 T cells represent a primary cell
type infected by HIV-1. Therefore, to assess the ability of
Oct-1 and Oct-2 to be employed as realistic inhibitors of
HIV-1, we explored the role of Oct proteins in HIV-1
transcription in primary human CD4 T cells. In this study,
we investigated the capacities of Oct-1 and Oct-2 to bind the
HIV-1 LTR in vitro. In addition, we analyzed the effect of
Oct-1 and Oct-2 overexpression in primary human CD4 T
cells on HIV-1 transcription and on virus production in HIV-
1-infected cells. Our results demonstrate that Oct-1 and Oct-
2 fail to bind to the HIV-1 LTR, and overexpression of Oct
proteins has no effect on HIV-1 transcription or replication
in primary human CD4 T cells.Results
Oct-1 and Oct-2 do not bind to the four putative sites within
the HIV-1 LTR
Although Liu and Latchman (1997) previously identified
four potential Oct binding sites within the HIV-1 LTR, no
binding studies were performed. We initially assessed bind-
ing by using nuclear extracts from BJA/B cells because they
are a rich source of Oct-1 and Oct-2 transcription factors. By
electrophoretic mobility shift assay (EMSA), factors from
this extract clearly showed the ability to bind an oligonu-
cleotide probe containing the Oct consensus binding se-
quence derived from the human immunoglobulin kappachain promoter (Fig. 2, lane 1). Two bands were revealed
and were shown to be specific by inhibition with excess
cold (unlabeled) self-competitor (lane 2). The upper band
was supershifted to the top of the gel with an anti-Oct-1
antibody (lane 3), and the lower band was supershifted with
an anti-Oct-2 antibody, demonstrating the specificities of
these two bands. However, this same nuclear extract failed
to bind to any of the four putative Oct binding sites from the
HIV-1 LTR (Fig. 2, lanes 5–8). Similar results were
obtained using nuclear extracts from activated primary
human CD4 T cells (data not shown). These results dem-
onstrate that neither Oct-1 nor Oct-2 is capable of binding in
vitro to any of the four previously identified putative Oct
binding sites within the HIV-1 LTR. This is not entirely
surprising because none of the four sites share more than six
of the eight consensus base pairs and two of the sites lack
the critical ATG motif.
Oct-1 and Oct-2 have no effect on HIV-1 transcription in
primary human CD4 T cells
Previously, Liu and Latchman (1997) demonstrated that
overexpression of Oct-1 or Oct-2 markedly inhibited basal
HIV-1 LTR-directed transcriptional activity in a fibroblast
cell line. Although we were unable to detect Oct binding to
the HIV-1 LTR in vitro, it remained possible that over-
expression of Oct proteins would still be able to alter HIV-1
transcription through an indirect mechanism(s). To deter-
mine the roles of Oct-1 and Oct-2 on HIV-1 LTR promoter
activity in primary CD4 T cells, freshly isolated human
peripheral blood CD4 T cells were transiently co-transfected
with pLTR-Luc (reporter plasmid) plus pCG (control), pCG-
Oct-1, or pCG-Oct-2 expression constructs by our own
established methodology (Cron et al., 1997). After 2 h of
rest, the cells were polyclonally activated for 6 h and
analyzed for luciferase activity. Compared with the empty
vector control (pCG), overexpression of Oct-1 or Oct-2
showed no significant effect on HIV-1 LTR-driven tran-
scription in primary CD4 T cells (Fig. 3). Similar results
were obtained without activation (data not shown). Because
Liu and Latchman (1997) had also previously shown that
Oct inhibited transactivation of the HIV-1 LTR by the HIV-1
Fig. 2. Oct-1 and Oct-2 do not bind to any of the four putative sites in the HIV-1 LTR. Nuclear protein from BJA/B cells was incubated with an Oct consensus
oligonucleotide (oct-con) or four similar sequences from the HIV-1 LTR (see Fig. 1) and analyzed by EMSA. The binding of Oct proteins to the Oct consensus
oligonucleotide (lane 1) was blocked by 200-fold excess of self-cold competition (lane 2) or by pre-incubation of the extract with anti-Oct-1 antibody (lane 3)
or anti-Oct-2 antibody (lane 4). No DNA–protein complexes were detected using the four sequences from the HIV-1 LTR (lanes 5–8). The experiment shown
is representative of five similar binding studies.
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the HIV-1 LTR reporter gene along with a Tat expression
vector and pCG, pCG-Oct-1, or pCG-Oct-2. As expected,
Tat expression augmented HIV-1 LTR transcriptional activ-
ity (an average of 4-fold, n = 2), but the presence of either
Oct-1 or Oct-2 substantially increased HIV-1 LTR reporterFig. 3. Oct-1 and Oct-2 have no significant effect on HIV-1 transcription in
primary human CD4 T cells. Primary human peripheral blood CD4 T cells
were transiently co-transfected with pLTR-Luc and pRL-null luciferase
reporter plasmids plus pCG-Oct-1, pCG-Oct-2, or pCG (control) expression
plasmids. The cells were then stimulated with PMA and ionomycin for 6 h.
Arbitrary firefly luciferase light units corrected for transfection efficiency
by Renilla luciferase light units are presented as mean values plus or minus
the standard errors of the means from one representative experiment of five.
The promoterless luciferase parent control vector for pLTR-Luc, pGL2-
Basic, consistently results in arbitrary light units under 2000.activity by an average of 18- and 9-fold, respectively (n =
2). These results are in stark contrast to those of Liu and
Latchman (1997) who showed that Oct inhibited HIV-1 LTR
activity as well as Tat-mediated transactivation of the HIV-1
LTR in a fibroblast cell line.
Oct-1 and Oct-2 have no effect on HIV-1 infection in
primary human CD4 T cells
To exclude the possibility that Oct proteins inhibit HIV-1
LTR activity in CD4 T cells via interaction with Tat or any
other HIV-1 accessory proteins, primary human peripheral
blood CD4 T cells were infected with HIV-1 in vitro. First,
to overexpress Oct proteins in a large percentage of primary
T cells, we employed a novel electroporation-based tech-
nology (Amaxa) that consistently transfects 50–80% of
freshly isolated human peripheral blood CD4 T cells in
our hands (Cron, 2003). Protein expression derived from
transfected plasmids can also be detected up to a week post-
electroporation (Cron, 2003). Using this approach, primary
CD4 T cells were co-transfected with pEGFP-N1 and pCG,
pCG-Oct-1, or pCG-Oct-2. The cells were then polyclonally
stimulated for 2 days to allow for HIV-1 infection. The CD4
T cells were then infected with the NL4-3 strain of HIV-1
and analyzed 3 days postinfection.
After 3 days of HIV-1 infection and 5 days post-trans-
fection with the Oct expression plasmids, the CD4 T cells
were analyzed for productive HIV-1 infection. First, over-
expression of Oct-1 and Oct-2 was confirmed at the protein
Fig. 5. Overexpression of Oct proteins has no effect on p24 production by
HIV-1-infected CD4 T cells. Freshly isolated primary human CD4 T cells
were co-transfected with pCG-Oct-1, pCG-Oct-2, or control plasmid (pCG)
plus a GFP marker plasmid (pEGFP-N1). The transfected T cells were
activated polyclonally with PHA (2 Ag/ml) and rhIL-2 (20 IU/ml) for 48
h and then infected with the NL4-3 strain of HIV-1. The culture media were
exchanged with fresh media at day 2 postinfection, and 24 h later
supernatants were harvested. p24/gag levels were detected in the
supernatants by ELISA. One representative experiment of six is shown.
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polyclonally activated CD4 T cells 2 days post-transfection
at the time of HIV-1 infection and 5 days post-transfection at
the time of HIV-1 infection analyses. The extracts were
analyzed for binding to an Oct consensus probe and nuclear
extracts from BJA/B cells were used as migration references
for Oct-1 and Oct-2 (Fig. 4, lane 1). Both the TE (lane 2)
and pCG (lane 3) control transfections revealed proteins
migrating identically to those from BJA/B cells. Unlike
BJA/B cells, in which there appears to be roughly equiva-
lent expression of Oct-1 and Oct-2, Oct-1 expression is
greater than Oct-2 in primary human CD4 T cells. In
addition, a faint and faster migrating band was also seen
in CD4 T cells (lanes 2–5). This is consistent with the fact
that lymphocytes express two isoforms of Oct-2, Oct-2A,
and Oct-2B (Schreiber et al., 1989). Overexpression of Oct-
1 revealed significantly increased binding of the uppermost
band (lane 4), but not the lower Oct-2 bands, whereas
overexpression of Oct-2 showed increased binding of Oct-
2B only (consistent with the cDNA present in pCG-Oct-2).
Similar, but less dramatic, results were seen at 5 days post-
transfection (lanes 6–9). Therefore, overexpression of Oct
proteins achieved by Amaxa electroporation led to signifi-
cant increases in the specific Oct proteins transfected, and
the increased levels were present at the time of infection and
throughout the period of infection.Fig. 4. Oct overexpression confirmed by EMSA. Primary CD4 T cells were transie
pCG (vector control, lanes 3 and 7), or TE (buffer control, lanes 2 and 6). Nuclear e
day 5 (lanes 6–9) after transfection and were analyzed for Oct expression by EMS
cells was used as a reference (lane 1). The migration patterns of Oct-1, Oct-2A, O
representative of three similar experiments.To analyze the effect of Oct overexpression on virus
production, p24 expression was analyzed. Specifically, 2
days after infection with HIV-1, the media were exchanged
with fresh media, and 24 h later the media were analyzedntly transfected with pCG-Oct-1 (lanes 4 and 8), pCG-Oct-2 (lanes 5 and 9),
xtracts were prepared from transfected CD4 T cells at day 2 (lanes 2–5) and
A using the Oct consensus probe as in Fig. 2. Nuclear extract from BJA/B
ct-2B, and free probe are listed to the left of the figure. Results shown are
M. Zhang et al. / Virology 321 (2004) 323–331 327for p24/gag expression by ELISA. As shown in Fig. 5,
overexpression of Oct-1 or Oct-2 had no significant effect
on p24 recovered in the supernatant compared with the
control expression vector. Thus, unlike overexpression of
other transcription factors, which can significantly alter p24
expression of HIV-1 virions or proviruses (Cron et al.,
2000) (and data not shown), overexpression of the Oct
proteins did not alter HIV-1 infection of primary CD4 T
cells.
Another measure of HIV-1 infection of CD4 T cells is
apoptosis, which occurs in both infected and bystander
CD4 T cells during HIV-1 infection (Selliah and Finkel,
2001a). To address whether overexpression of Oct proteins
modified HIV-1 enough to alter apoptosis, primary human
CD4 T cells were transfected with the Oct expression
plasmids together with a green fluorescent protein (GFP)
expression plasmid. As above, the transfected cells were
polyclonally stimulated for 2 days in vitro and then
infected with the NL4-3 strain of HIV-1 for an additional
3 days. Apoptosis of the CD4 T cells was assayed by flow
cytometry; apoptotic cells were identified by staining with
Annexin V and 7AAD. GFP fluorescence was used as a
marker of Oct-transfected cells because we have previouslyFig. 6. Overexpression of Oct proteins has no effect on apoptosis of HIV-1-infected
cells were mock transfected with TE (diluent control) or co-transfected with pCG
(pEGFP-N1). The transfected T cells were activated and then infected with the NL4
day 3 postinfection by staining for Annexin V ( y-axis) and 7AAD (x-axis). Dot p
and GFP/p24 populations. The numbers listed in the lower right quadrants repre
cells include Annexin V and 7AAD, single and double positive cells. Results frodemonstrated by fluorescence microscopy the coordinate
transfection of two different fluorescent labeled plasmids
by the Amaxa transfection methodology (M.Z. and R.Q.C.,
unpublished data) as well as by our own transfection
protocol (Cron et al., 1997). As seen in Fig. 6, after 3
days of HIV-1 infection, there was little difference in
levels of apoptosis among infected (p24+) or bystander
(p24) CD4 T cells, whether they were transfected with
Oct-expressing plasmids (GFP+) or not (GFP and pCG
control transfected). On average, from a total of six
experiments, there was no consistent difference in levels
of apoptosis detected in HIV-1-infected and bystander T
cells comparing cells overexpressing either Oct-1 or Oct-2
relative to controls. Moreover, in each sample, the percen-
tages of GFP+ cells were similar among cells transfected
with pCG (control), pCG-Oct-1, or pCG-Oct-2. Lastly, the
p24+ percentages were comparable in the pCG (control),
pCG-Oct-1, and pCG-Oct-2 groups (data not shown),
confirming the results in Fig. 5. Thus, analysis of apopto-
sis among HIV-1-infected and bystander CD4 T cells
confirmed the p24 analyses showing that overexpression
of Oct proteins in primary human CD4 T cells has little to
no effect on HIV-1 infection.and bystander CD4 T cells. Freshly isolated human peripheral blood CD4 T
-Oct-1, pCG-Oct-2, or control plasmid (pCG) plus a GFP marker plasmid
-3 strain of HIV-1 as in Fig. 5. Apoptosis was assayed by flow cytometry at
lot profiles are shown after gating on GFP+/p24+, GFP+/p24, GFP/p24+,
sent the total apoptosis percentages for each population, in which apoptotic
m one representative experiment of six are shown.
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In this study, we have explored the ability of Oct-1 and
Oct-2 proteins to regulate HIV-1 transcription in primary
human CD4 T cells. We hypothesized that Oct proteins
might repress HIV-1 replication in primary human CD4 T
cells for the following reasons. First of all, overexpression
of either Oct-1 or Oct-2 in HeLa cells or BHK cells
dramatically repressed both the basal activity of the HIV-1
LTR and its transactivation by Tat (Liu and Latchman,
1997). Next, both Oct-1 and Oct-2 are capable of augment-
ing the T cell-derived cytokine IL-2 (Cron et al., 2001;
Kamps et al., 1990). The ability of Oct proteins to augment
IL-2 production might be of benefit to the infected host
because HIV-1 leads to the progressive loss of CD4 T cells
and IL-2 may facilitate their recovery (Katlama et al., 2002;
Levy et al., 2003). Moreover, Oct proteins’ capacity to
inhibit IL-4 transcription (Cron et al., 2001; Wysocka and
Herr, 2003) suggested that they are candidates to promote a
Th1 rather than a Th2 pattern of cytokine gene expression in
activated CD4 T cells. This might also counter HIV-1
infection because the virus replicates more efficiently in
Th2 cells (Mwinzi et al., 2001) and progressive decline in
HIV-1-infected individuals has been shown to correlate with
a loss of Th1 function (Clerici et al., 1993), important for
the elimination of intracellular pathogens. Therefore, over-
expression of Oct proteins might inhibit HIV-1 transcription
and replication.
From our study, however, overexpression of Oct-1 or
Oct-2 alone had no effect on HIV-1 LTR reporter gene
activity in primary human CD4 T cells (Fig. 3). This was not
due to the inability of this reporter gene to be affected by
overexpression of transcription factors by transient trans-
fection in primary human CD4 T cells because we have
previously demonstrated the ability of NFAT transcription
factors to markedly augment HIV-1 LTR activity under
identical conditions (Cron et al., 2000). Nor was the lack
of effect of Oct proteins on HIV-1 transcription due to the
Oct expression plasmids employed in these studies because
the identical plasmids either augmented or inhibited IL-2 or
IL-4 transcription, respectively, under the same circumstan-
ces (Cron et al., 2001). This is also not entirely surprising
because Oct proteins are incapable of binding to any of the
previously identified putative Oct binding sites within the
HIV-1 LTR (Fig. 2). Lastly, overexpression of Oct-2 along
with its co-factor, OCA-B, did not change HIV-1 LTR
activity in primary CD4 T cells compared to overexpression
of Oct-2 plus the control vector for OCA-B (data not
shown). These studies, however, were all conducted in
vitro, and it remained possible that Oct proteins could alter
HIV-1 during infection.
Until very recently, it has been difficult to overexpress
proteins of interest in primary human CD4 T cells. One
approach has been to introduce genes using retroviruses
(Curran et al., 2000). However, this approach is less than
ideal when studying retroviruses themselves, such as HIV-1.In this study, we have taken advantage of a novel commer-
cially available electroporation technique which allows for
efficient introduction of plasmid DNA into primary human
CD4 T cells (Cron, 2003). Because expression of the
plasmid DNA persists for up to a week post-transfection
(Cron, 2003), we have been able to develop a protocol that
not only permits overexpression of a gene(s) of interest but
also allows for HIV-1 infection of the same population of
primary CD4 T cells (see Materials and methods). With this
approach, we established that Oct overexpression had little
to no effect on HIV-1 infection in primary human CD4 T
cells as detected by p24 expression and by analysis of
apoptosis of infected and bystander CD4 T cells (Figs. 5
and 6). It is possible that overexpression of Oct is not
detectable until 4 days postinfection, but overexpression of
other transcription factors in primary human CD4 T cells has
demonstrated effects on HIV-1 expression within this time
frame (Cron et al., 2000) (and data not shown). Because
these were essentially negative results, we went on to
demonstrate that the Oct proteins from transfected plasmids
were indeed overexpressed at the protein level, and in
addition, were capable of binding to DNA (Fig. 3). It is
therefore very likely that overexpression of Oct transcription
factors has little to no effect on HIV-1 transcription in
primary human CD4 T cells, at least within the first 3 days
of infection.
These studies demonstrate the importance of analyzing
HIV-1 transcription in cell types that are actually infected by
HIV-1. Moreover, because primary cells differ in many
respects from cell lines and tumors (Cron et al., 1997;
Hughes and Pober, 1996), it is important to study HIV-1
infection in primary human CD4 T cells. Lastly, although we
were unable to demonstrate a role for Oct overexpression in
primary CD4 T cells, Moriuchi and Moriuchi (2001) have
reported that overexpression of Oct-2 or octamer coactivator
BOB.1/OBF/OCA-B can increase the expression of CCR5,
a major co-receptor for macrophage-tropic HIV-1, and the
fusogenicity of the cells with R5 HIV-1 Envelope. Thus,
further exploration of the role of Oct transcription factors
during HIV-1 infection may be warranted.Materials and methods
Plasmids and reagents
The expression vectors pCG-Oct-1, pCG-Oct-2, and
pCG (the parent control) were generously provided by Dr.
Winship Herr (Cold Spring Harbor, NY) (Tanaka and Herr,
1990). The Tat expression vector pSV-Tat72 and control
vector pSV2-neo were kindly provided by Dr. Dennis
Kolson (University of Pennsylvania, Philadelphia, PA)
(Kolson et al., 1994), and the OCA-B/OBF/BOB.1 and
control [pcDNA3.1()] expression vectors were kindly
provided by Dr. Robert Roeder (Rockefeller University,
New York, NY) (Luo et al., 1992). The green fluorescent
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chased from Clontech (Palo Alto, CA). The pLTR-Luc
reporter construct generated by subcloning the 3V HIV-1
LTR segment into the polylinker of the promoterless pGL2-
Basic firefly luciferase reporter gene (Promega, Madison,
WI) has been previously reported (Klebanoff et al., 1994).
The Renilla luciferase-expressing transfection control plas-
mid pRL-null was obtained from Promega. The lectin
phytohemagglutinin (PHA), the phorbol ester phorbol myr-
istate acetate (PMA), the calcium ionophore ionomycin, and
7-aminoactinomycin D (7AAD) were obtained from Sigma
(St. Louis, MO). Anti-Oct-1 and anti-Oct-2 antibodies were
acquired from Santa Cruz Biotechnology (Santa Cruz, CA).
Phycoerythrin-conjugated anti-HIV-1 core antigen (p24)
antibody, the ELISA kit for HIV-1 p24 Ag detection, and
Annexin V staining reagents were products of Beckman
Coulter (Miami, FL). Recombinant human IL-2 was
obtained freely from the NIH AIDS Research and Reference
Reagent Program. HIV-1 molecular clone NL4-3 was kindly
provided by Dr. Terri H. Finkel (The Children’s Hospital of
Philadelphia, PA).
CD4 cell isolation
Adult human CD4 T cells were isolated from the periph-
eral blood of healthy adult volunteers by negative selection
using a proprietary antibody mix (StemCell Technologies,
Vancouver, BC) and red blood cell rosetting as previously
described (Cron, 2001; Lansdorp and Thomas, 1990). In
brief, freshly isolated human peripheral blood was incubated
with CD4 T cell enrichment cocktail (monoclonal antibodies
to CD8, CD16, CD19, CD36, and CD56) and incubated for
20 min at room temperature. The sample was then diluted
with PBS, layered onto a Ficoll-hypaque gradient, and
centrifuged for target cell enrichment. CD4 T cell purity
ranged from 90% to 97% as detected by flow cytometry
(data not shown).
Transient transfection luciferase reporter assays
Primary human peripheral blood CD4 T cells were
transiently co-transfected with pLTR-Luc (5 Ag/5 million
cells), pRL-null (1 Ag), and pCG (control), pCG-Oct-1, or
pCG-Oct-2 (10 Ag) by electroporation as described else-
where (Cron et al., 1997). In Tat-mediated HIV-1 LTR-
luciferase reporter assays, the Tat expression plasmid (10
Ag) or its empty control vector was co-transfected as a third
plasmid. The OCA-B expression plasmid (10 Ag) was also
co-transfected in select studies evaluating Oct-2 effects on
HIV-1 transcription. After electroporation and 2 h rest at
37 jC, CD4 T cells were stimulated in vitro with PMA (25
ng/ml) and ionomycin (1.5 AM) for 6 h at 37 jC. Cell
lysates were generated with Passive Lysis Buffer (Promega)
as previously described (Cron et al., 1999). Firefly lucifer-
ase reporter activity was determined in duplicate and cor-
rected for transfection efficiency based on Renilla luciferaseactivity (Dual Luciferase Assay Kit, Promega) using a
Lumat LB 9507 luminometer (EE and G Berthold, Bad
Wildbad, Germany) as previously detailed (Behre et al.,
1999; Cron et al., 2000).
Transient overexpression of Oct proteins in primary human
CD4 T cells
Primary human CD4 T cells were transfected with a
mixture of plasmid DNA by a novel electroporation-based
technology, Amaxa Nucleofector (Koln, Germany), as pre-
viously described (Cron, 2003; Lenz et al., 2003). We
previously determined the optimal ratio of pEGFP-N1 to
pCG-based Oct expression plasmids to be 1:5 to maximize
dual expression of the plasmids (data not shown). For each
Amaxa nucleotransfection reaction, 6 million primary CD4
T cells were incubated with 2.4 Ag of total plasmid DNA.
After transfection and 2 h rest at 37 jC, the cells were
cultured in complete medium (CM) (Cron et al., 1999)
supplemented with PHA (2.0 Ag/ml) and IL-2 (20 U/ml)
at 37 jC in humidified 5% CO2 for 2 days to allow for HIV-
1 infection.
HIV-1 infection of CD4 T cells
CD4 T cells were transfected with GFP- and Oct-expres-
sion plasmids and were cultured as above. The cells were
infected 2 days later with the NL4-3 strain of HIV-1 at a
multiplicity of infection (MOI) of 0.1 as previously detailed
(Selliah and Finkel, 2001b). The cells were then cultured in
CM with 20 U/ml IL-2 at 37 jC in humidified 5% CO2 for
an additional 3 days before analysis.
p24/gag detection
The culture media of infected primary CD4 T cells were
replaced completely with fresh media after 2 days of
infection. Twenty-four hours later, the culture media were
harvested for p24 detection. The cultural supernatants were
first diluted 1:100 with media and then assayed in triplicate
for p24/gag detection by ELISA, covering a standard range
of 7.8–250 pg/ml. The commercial (Beckman Coulter)
ELISA detection method has been described elsewhere
(Novick et al., 1996).
Analysis of apoptosis
Three days after infection, HIV-1-infected (p24+) and
bystander (p24) CD4 T cells were analyzed by flow
cytometry for evidence of apoptosis using 7AAD and
Annexin V staining as previously described (Selliah and
Finkel, 2001a). The cells were analyzed using FACSCalibur
(Becton Dickinson, San Jose, CA). GFP expression
(detected using FITC parameters, FL1) represented Oct
overexpressing cells, p24 expression (detected with anti-
p24-Phyco-erythrin, FL2) represented infected cells, and
M. Zhang et al. / Virology 321 (2004) 323–3313307AAD bound to DNA (detected using FL3) or Annexin V
expression (detected by anti-Annexin V-biotin followed by
strepavidin-APC, FL4) represented apoptotic cells. The data
were analyzed with CellQuest software (Becton Dickinson)
as previously described (Cron et al., 1999).
Nuclear protein preparation and EMSA
Nuclear proteins from BJA/B cells (kindly provided by
Dr. Stephan A. Grupp, University of Pennsylvania, Phila-
delphia, PA) or from transiently transfected primary human
CD4 T cells were extracted as previously described
(Schreiber et al., 1989). Oligonucleotides used as 32P-
labeled probes or as unlabeled competitors are listed in
Fig. 1. Electrophoretic mobility shift assays (EMSAs) were
performed as previously described (Dolganov et al., 1996).
In brief, 2 Ag of nuclear protein, 25000 cpm of 32P-labeled
probe, and EMSA binding buffer (500 mM Tris–HCI, pH
7.5; 500 mM KCL; 15 mM MgCl2; 10 mg/ml BSA; 50%
glycerol; 5 mg/ml single strand sperm DNA; 1 mM DTT)
were mixed and incubated 20 min on ice. For specificity
determinations, nuclear protein was reacted with excess
(200-fold) unlabeled probe or 2 Al of Oct-specific antibodies
30 min before the addition of labeled probe. The mixtures
were then electrophoresed on 6% gradient pre-poured DNA
retardation gels (Novex, San Diego, CA). Radioactive bands
were detected by conventional autoradiography.Acknowledgments
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